Abstract:3607 Background: Although the anti-tumor properties of vitamin D in colorectal cancer (CRC) have been broadly reported, its potential role as a tumor microenvironment (TME) immunomodulator has not been well established. Vitamin D receptor (VDR) and CYP27B1 (1-α-hydroxylase; required to convert vitamin D to its active form) are critical factors in the vitamin D signaling pathway and harbor prognostic significance for CRC. Pre-clinical studies suggest that higher stromal VDR expression enhances chemotherapy efficacy. To characterize the effects of vitamin D on the TME in humans, we conducted a randomized placebo-controlled trial of preoperative high-dose vitamin D supplementation in stage I-III colon cancer patients. Methods: Forty-two patients were randomized to receive vitamin D3 50,000 IU/day x 7 days followed by 10,000 IU/day versus placebo prior to resection. Paired pre-treatment biopsy specimens and post-treatment surgical resection specimens from 19 patients who completed the assigned treatment and had sufficient tissue for analysis were collected for spatially-resolved immune cell profiling and evaluation of VDR and CYP27B1 expression using custom multiplex immunofluorescence. Blood samples were collected pre- and post-treatment to assess plasma 25-hydroxyvitamin D [25(OH)D] levels. Linear mixed effects models were used to compare tissue parameters; plasma 25(OH)D level changes were assessed using the Wilcoxon rank-sum test. Results: Patients randomized to high-dose vitamin D had increased post-treatment plasma 25(OH)D (median 18.0 to 63.6 (ng/ml)) whereas placebo-randomized patients did not (median 19.1 to 18.6 (ng/ml)) ( p <0.001). Analysis of both biopsy and resection tissue revealed highly heterogeneous VDR and CYP27B1 expression. VDR expression was highest in tumor cells, followed by immune and then stromal cells. Although resection tissue from vitamin D-treated patients showed lower VDR expression than specimens from placebo-treated patients in all cells ( p= 0.03), VDR was preferentially expressed by tumor cells at the tumor invasive front compared to tumor center in the vitamin D arm, while the opposite was observed in the placebo arm. Vitamin D supplementation did not alter CYP27B1 expression. While treatment did not change total immune cell density, resection tissue from vitamin D-treated patients had higher overall CD3 + CD8 + T cell density ( p= 0.04), particularly CD3 + CD8 + memory T cell density ( p= 0.02). Additionally, vitamin D supplementation led to greater co-localization between CD3 + CD8 + T cells and tumor cells ( p< 0.001) compared to placebo. Conclusions: In patients with stage I-III CRC, vitamin D supplementation led to changes in vitamin D pathway signaling and evidence of an anti-tumor effect in the TME. Further investigation into the underlying mechanism of action is warranted. Clinical trial information: NCT02172651 .

Connecting vitamin D, the microbiome and anticancer immunity

Vitamin D regulates microbiome-dependent cancer immunity

Vitamin D-dependent microbiota-enhancing tumor immunotherapy

Microbes and vitamin D aid immunotherapy

Dietary vitamin D is a novel modulator of tumor engraftment through regulation of GC protein abundance

The Role of Microbiota-Derived Vitamins in Immune Homeostasis and Enhancing Cancer Immunotherapy

Vitamin D receptor protects against dysbiosis and tumorigenesis via the JAK/STAT pathway in intestine

Extraintestinal roles of intestinal vitamin D receptor in protecting against dysbiosis and tumorigenesis in breast cancer

Intestinal vitamin D receptor protects against extraintestinal breast cancer tumorigenesis

Vitamin D and colorectal cancer: Chemopreventive perspectives through the gut microbiota and the immune system

Microbiota Modulate Tumoral Immune Surveillance in Lung Through a Γδt17 Immune Cell-Dependent Mechanism.

The Gut Microbiome, Microsatellite Status and the Response to Immunotherapy in Colorectal Cancer

Impact of vitamin d on the colon tumor immune microenvironment: Results of a randomized clinical trial of preoperative vitamin D supplementation in patients with stage I-III colon cancer.

Exploring the Role of Vitamin D and the Vitamin D Receptor in the Composition of the Gut Microbiota

Eating away cancer: the potential of diet and the microbiome for shaping immunotherapy outcome

Vitamin D Controls Tumor Growth and CD8+ T Cell Infiltration in Breast Cancer

Vitamin D Status after Colorectal Cancer Diagnosis and Patient Survival According to Immune Response to Tumour.

Unraveling colorectal cancer prevention: The vitamin D - gut flora - immune system nexus

The gut microbiome modulate response to immunotherapy in cancer